ArticleOncotarget2015

Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.

Donglin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.